Enanta Pharmaceuticals, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a standalone Q4 earnings report; the filing does not provide separate Q4 financial results. Amounts below are in U.S. dollars.
Business context
Enanta is a biotechnology company developing small-molecule treatments, primarily for viral infections. Its principal source of revenue is royalties from AbbVie’s HCV treatment MAVYRET/MAVIRET, which contains Enanta-discovered glecaprevir. Enanta’s wholly owned programs target RSV, SARS-CoV-2, HBV and hMPV. Its pipeline candidates had not advanced beyond Phase 2.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Royalty revenue | $86.2 million | $97.1 million |
| Research and development expense | $164.5 million | $174.1 million |
| General and administrative expense | $45.5 million | $32.5 million |
| Operating loss | $123.8 million | $109.6 million |
| Net loss | $121.8 million | $79.0 million |
| Net loss per share, basic and diluted | $5.91 | $3.92 |
| Cash used in operating activities | $84.8 million | $70.0 million |
- Revenue consisted of royalties. It declined 11% year over year as AbbVie reported lower HCV sales; the weighted-average royalty rate on allocated sales was approximately 11% in both years.
- Operating expenses totaled $210.0 million, up from $206.6 million. Virology R&D spending increased by $16.9 million, partly offset by a $26.3 million reduction in non-viral liver-disease spending as the NASH program wound down.
- The FY2022 operating loss was about 144% of revenue (calculated). The filing does not present this as a reported margin.
- Cash, cash equivalents and short- and long-term marketable securities totaled $278.5 million at year-end, compared with $352.4 million a year earlier. Management expected these resources and continuing HCV royalties to fund R&D into approximately Q4 FY2024.
- Current assets were $311.7 million and current liabilities were $29.8 million. Enanta reported no debt outstanding. Total liabilities were $54.1 million, including operating lease liabilities.
Material changes and notable items
- Net loss increased by $42.8 million year over year. The comparison is affected by a $28.6 million income-tax benefit in FY2021, largely related to CARES Act loss carrybacks; FY2022’s tax benefit was $0.4 million.
- Operating cash use rose by $14.8 million, primarily due to lower royalty receipts. The company also reported $21.3 million of proceeds from stock-option exercises in FY2022.
- Enanta entered into expanded Watertown, Massachusetts lease arrangements, including a new ten-year lease for a facility expected to become available for tenant improvements in October 2023. The new lease’s estimated minimum payments total $76.5 million over its term; the filing also cites approximately $7.6 million of expected capital expenditures for additional space and a potential $2.6 million tenant-improvement allowance.
Outlook, pipeline and risks
- Management expected continued net losses in FY2023, with R&D expenses generally increasing as programs advance. The cash-runway estimate depends on future AbbVie royalties and spending and is subject to uncertainty.
- EDP-938’s Phase 2 RSVP study did not meet its primary symptom endpoint or secondary antiviral endpoints in otherwise healthy adults. A greater proportion of treated subjects had undetectable RSV RNA at Day 5; the company reported favorable safety and continued development in higher-risk populations.
- EDP-235 completed Phase 1 in July 2022 with reported tolerability and exposure results. The Phase 2 SPRINT study began in November 2022, after fiscal year-end. EDP-323’s Phase 1 study began in October 2022, also after year-end. EDP-514 Phase 1b results supported continued HBV development, with a combination-treatment approach as the stated goal.
- Key risks include dependence on AbbVie’s HCV sales, continuing HCV market and pricing pressure, and the potential for COVID-19-related changes in diagnosis and treatment to affect royalties. Enanta also cited uncertain RSV incidence and enrollment, clinical and regulatory failure risk, competition, reliance on third-party manufacturers and CROs, and the need for additional funding beyond the projected runway.
- Enanta filed a patent-infringement suit against Pfizer in June 2022 concerning Paxlovid and sought damages. The filing says associated legal expenses are recorded as incurred; it does not report a resolution.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor also opined that internal controls were effective. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Subsequent AbbVie MAVYRET/MAVIRET sales, pricing, market share and royalty receipts, including the impact of the annual royalty-tier reset.
- Actual cash burn and whether liquidity continues to support operations on the stated timeline into approximately Q4 FY2024.
- Enrollment, safety and efficacy outcomes in the ongoing higher-risk RSV trials, given the RSVP results and unpredictable RSV seasonality.
- EDP-235 Phase 2 progress and whether clinical benefit, safety and regulatory requirements support further development.
- Costs and developments in the Pfizer patent litigation, as well as lease-related commitments and future facility spending.